Business Context and Reporting Period
Company: Omeros Corporation
Filing Type: Form 8-K (Current Report)
Date of Report: November 22, 2010
Event: Completion of acquisition of intellectual property assets from Patobios Limited related to an assay technology for Omeros' G protein-coupled receptor (GPCR) program.
Key Financial Metrics
Acquisition Cost: $10.8 million CAD total purchase price.
Payment Structure:
- Cash: $7.8 million CAD
- Equity: 379,039 shares of Omeros common stock (valued at $3.0 million CAD)
Other Metrics: The filing text does not provide clear values for revenue, profit, cash flow, margins, debt, or liquidity beyond the specific transaction details.
Material Changes
The primary material change is the expansion of Omeros' intellectual property portfolio through the acquisition of the Patobios assay technology. Additionally, the company issued 379,039 shares of unregistered common stock in an offshore transaction exempt under Regulation S.
Guidance, Outlook, and Risks
Management Commentary: The acquisition was executed pursuant to an Exclusive Technology Option Agreement dated September 4, 2008, as amended. A press release announcing the closing was issued on November 23, 2010.
Risks and Contingencies: The filing does not explicitly detail new risks or contingencies arising from this transaction, other than the standard implications of asset acquisition and equity issuance.
Investor Verification Checklist
- Verify the fair market value of the 379,039 shares issued to Patobios at the time of the transaction.
- Confirm the remaining balance and terms of the $20.0 million funding agreement with Cougar Investment Holdings LLC.
- Review the attached press release (Exhibit 99.1) for further details on the strategic impact of the GPCR assay technology.
- Check subsequent filings for any dilution impact from the unregistered stock issuance.